fda statement bpc-157 not approved drug panel backs compounded BPC-157, KPV peptides in win for RFK Jr FDA panel narrowly backs unapproved

Forsyth JC, Mueller PD, Becker ChE, Osterloh J, Benowitz NL, Rumack BH, Hall AH

The method of any one of embodiments 39-57, wherein the composition has a viscosity between about 10 cP to about 10,000 cP, about 10 cP to about 5,000 cP, about 10 cP to about 1,000 cP, about 10 cP to about 500 cP, about 10 cP to about 250 cP, about 10 cP to about 100 cP, or about 10 cP to about 50 cP

Some people choose to have B12 injections, but be sure to obtain medical advice before going ahead with this method of consuming this vitamin

(Reply to Jozwiak et al

Important context BPC-157 has not undergone the regulatory review required for pharmaceutical drugs

Outcome measures cover histological damage scoring, cytokine panels (TNF-, IL-6, IL-10), mucosal blood flow, tight junction protein expression by Western blot, and stool consistency scoring for colitis models